An ongoing dialogue on HIV/AIDS, infectious diseases,
June 15th, 2012
ID Learning Unit — The D Test
I suppose it’s not surprising that we’d follow-up the Etest with the D test, though perhaps if I were being alphabetical, the order would have been reversed. The D test is important, because it screens for a form of clindamycin resistance in MRSA that might otherwise not be detected — the “inducible” kind, which can […]
June 13th, 2012
Questions About HIV Cure, and a Very Funny Quote
The single case of HIV cure following allogeneic bone marrow transplant is in the news again, this time because of data just presented at “The International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies” (formerly known as the “HIV Resistance Workshop” — how’s that for rebranding?). I’m not at the meeting, which is […]
June 12th, 2012
ID Learning Unit — The Etest
Every year I attend on the general medical service, so it gives me a chance to work directly with the medical residents — and to brush up on my non-ID-related Internal Medicine. In exchange for what they teach me, each day on rounds I try to tell them about at least one ID-related thing that […]
June 8th, 2012
SPARTAN: Two-Drug, NRTI-Sparing Strategies Continue to Disappoint
Just published is the cleverly named “SPARTAN” study — spartan because it leaves out both NRTIs and ritonavir — and the results are very interesting. Ninety-three treatment-naive HIV-positive study subjects were randomized 2:1 to receive either a two-drug regimen of raltegravir 400 mg BID + atazanavir 300 mg BID, or a standard regimen of TDF/FTC + boosted […]
June 6th, 2012
A Fun Internet Poll for ID Nerds
Over on Medscape, one of my ID heroes, John Bartlett, has a new series called, “The Medscape Awards in Infectious Diseases” and it looks like a winner. Here’s how it works: The Medscape Awards in Infectious Diseases is a new series that will honor the greatest achievements in the field of infectious diseases during 1980-2012. […]
June 2nd, 2012
Cryptococcal Meningitis Study Stopped — Early HIV Therapy Clearly Harmful
From NIAID, an important clinical trial has been stopped early: The Phase IV study … was evaluating whether HIV-infected participants hospitalized with cryptococcal meningitis (CM) but not yet taking antiretroviral therapy (ART) would improve their chances of survival if they began ART while receiving CM treatment as inpatients compared with the standard practice of beginning […]
May 30th, 2012
Little Fluffy Baby Chicks Spread Deadly Intestinal Infection
Sorry for the headline, but that was the first thing I thought of when reading this paper just published in the New England Journal of Medicine: In this report, we describe a prolonged and ongoing multistate outbreak of human salmonella infections primarily affecting young children and linked to contact with live young poultry from a […]
May 20th, 2012
News on HIV and HCV Testing, and in Praise of Accurate Screening Tests
Two recent news items reminded me how lucky we are to have some very accurate screening tests for certain infectious diseases. The news: An expert FDA panel backed approval of the first true home test for HIV, the OraQuick mouth swab test. Approval of OraQuick for home use may occur later this year. While home […]
May 16th, 2012
Azithromycin Linked to Cardiovascular Death — Not A Placebo After All
I’ve commented before about azithromycin, that remarkable antibiotic that clinicians seem to prescribe for, gosh, you-name-it. But a paper just published in the New England Journal of Medicine links use of azithromycin to an increased risk of cardiovascular death, a reminder that “azithro” is in fact a drug — and that all drugs have side […]
May 10th, 2012
Advisory Meeting Today on Tenofovir/FTC for PrEP, and a Proposed “Niche” for its Use
From Bloomberg News: Gilead Sciences Inc.’s pill Truvada was safe and effective when used to protect uninfected people from getting HIV, U.S. regulators said in a report indicating the main concerns are when and how it should be used … The FDA asked its advisers to suggest who should get Truvada; what testing would be […]
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Interactive Perspective: Measles December 18, 2025This Double Take video reviews evidence-based recommendations on measles prevention and management and explores commonly asked questions about the measles virus and infection.
- Noninferiority of One HPV Vaccine Dose to Two Doses December 18, 2025In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection.
- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 18, 2025In recent years, cases of congenital syphilis have surged. This trend reflects both prenatal care gaps and systemic issues, including failures in testing, treatment, and public health infrastructure.
- Contact Precautions for MRSA and Vancomycin-Resistant Enterococcus December 18, 2025This feature about the use of contact precautions in the hospital for patients with MRSA or VRE offers a case vignette accompanied by two essays, one supporting continuing the use of contact precautions and the other recommending discontinuing them.
- Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection December 18, 2025Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial...
- Interactive Perspective: Measles December 18, 2025